GNAS is often analyzed along KRAS (11,15–17,22,23) or other MAPK pathway genes (BRAF, HRAS, NRAS) (18,33) to improve the detection of IPMN and MCN. This evidence concerns the gene HRAS and pancreatic intraductal papillary-mucinous neoplasm.